$11.53
-0.31-2.62%
Last update: 11:59 AM
15 minutes delayed
Comments
Loading...
Astria Therapeutics
ATXSNASDAQ
want to know what
the Bulls & Bears Say?
Astria Therapeutics (NASDAQ:ATXS) Stock, Analyst Ratings, Price Targets, Forecasts
Astria Therapeutics Inc has a consensus price target of $21.6 based on the ratings of 5 analysts. The high is $27 issued by Jefferies on March 25, 2024. The low is $16 issued by HC Wainwright & Co. on May 10, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and Wedbush on May 21, 2024, May 10, 2024, and May 10, 2024, respectively. With an average price target of $21 between Oppenheimer, HC Wainwright & Co., and Wedbush, there's an implied 82.13% upside for Astria Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Wedbush
Jefferies
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Astria Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/21/2024 | Buy Now | 116.83% | Oppenheimer | Hartaj Singh | $29 → $25 | Maintains | Outperform | Get Alert |
| 05/10/2024 | Buy Now | 38.77% | HC Wainwright & Co. | Joseph Pantginis | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 90.81% | Wedbush | Laura Chico | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 04/23/2024 | Buy Now | 38.77% | HC Wainwright & Co. | Joseph Pantginis | $18 → $16 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 90.81% | Wedbush | Laura Chico | → $17 | Maintains | Outperform | Get Alert |
| 03/25/2024 | Buy Now | 134.17% | Jefferies | Eun Yang | $22 → $27 | Maintains | Buy | Get Alert |
| 03/25/2024 | Buy Now | 56.11% | HC Wainwright & Co. | Joseph Pantginis | $18 → $18 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 56.11% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 47.44% | Wedbush | Laura Chico | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 03/05/2024 | Buy Now | 56.11% | HC Wainwright & Co. | Joseph Pantginis | — | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | Buy Now | 47.44% | Wedbush | Laura Chico | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 11/15/2023 | Buy Now | 116.83% | Oppenheimer | Hartaj Singh | $30 → $25 | Maintains | Outperform | Get Alert |
| 10/13/2023 | Buy Now | 56.11% | Wedbush | Laura Chico | $25 → $18 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | 56.11% | HC Wainwright & Co. | Joseph Pantginis | $20 → $18 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 116.83% | Wedbush | Laura Chico | $26 → $25 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 73.46% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | 160.19% | Oppenheimer | Hartaj Singh | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 125.5% | Wedbush | Laura Chico | → $26 | Reiterates | → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 73.46% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2023 | Buy Now | 56.11% | Evercore ISI Group | Liisa Bayko | → $18 | Initiates | → Outperform | Get Alert |
| 02/24/2023 | Buy Now | 73.46% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | Buy Now | 73.46% | HC Wainwright & Co. | Joseph Pantginis | $13 → $20 | Maintains | Buy | Get Alert |
| 09/29/2021 | Buy Now | 73.46% | Jefferies | Eun Yang | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Astria Therapeutics (ATXS) stock?
The latest price target for Astria Therapeutics (NASDAQ:ATXS) was reported by Oppenheimer on May 21, 2024. The analyst firm set a price target for $25.00 expecting ATXS to rise to within 12 months (a possible 116.83% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
The latest analyst rating for Astria Therapeutics (NASDAQ:ATXS) was provided by Oppenheimer, and Astria Therapeutics maintained their outperform rating.
When was the last upgrade for Astria Therapeutics (ATXS)?
There is no last upgrade for Astria Therapeutics
When was the last downgrade for Astria Therapeutics (ATXS)?
There is no last downgrade for Astria Therapeutics.
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on May 21, 2024 so you should expect the next rating to be made available sometime around May 21, 2025.
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a maintained with a price target of $29.00 to $25.00. The current price Astria Therapeutics (ATXS) is trading at is $11.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.